Gary M. Clark spends much of his time researching Internal medicine, Breast cancer, Oncology, Pathology and Mammary gland. His study in Endocrinology extends to Internal medicine with its themes. His biological study spans a wide range of topics, including Immunohistochemistry, Cancer research, Treatment decision making, Neoplasm staging and Oncogene.
His Oncology study combines topics in areas such as Aneuploidy, Survival rate, Disease, Gene duplication and Flow cytometry. His Mammary gland research is multidisciplinary, incorporating elements of Estrogen and Lymph node. In his research on the topic of Cancer, Trastuzumab, Neratinib, HER2/Neu Status, HER2/neu and Lapatinib is strongly related with Immunology.
Gary M. Clark mainly focuses on Internal medicine, Breast cancer, Oncology, Pathology and Cancer. His Internal medicine study incorporates themes from Endocrinology and Surgery. Gary M. Clark combines subjects such as Immunohistochemistry, Cancer research and Estrogen with his study of Breast cancer.
His studies deal with areas such as Proportional hazards model, Disease, Immunology and Survival rate as well as Oncology. When carried out as part of a general Pathology research project, his work on Carcinoma is frequently linked to work in Context, therefore connecting diverse disciplines of study. His study on Cancer is mostly dedicated to connecting different topics, such as In vitro.
His main research concerns Internal medicine, Oncology, Breast cancer, Pathology and Cancer. Internal medicine and Endocrinology are commonly linked in his work. His Oncology research is multidisciplinary, relying on both Radiation therapy, Incidence, Survival rate, Proportional hazards model and Survival analysis.
His research in Breast cancer intersects with topics in Cancer research, Lymph node and Race. His work on Carcinoma as part of general Pathology study is frequently connected to Context, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. Gary M. Clark interconnects Immunohistochemistry, Axillary lymph nodes and Estrogen in the investigation of issues within Mammary gland.
Internal medicine, Breast cancer, Oncology, Pathology and Cancer are his primary areas of study. His study ties his expertise on Endocrinology together with the subject of Internal medicine. His Pathology research includes themes of MEDLINE and Intensive care medicine.
His studies examine the connections between Erlotinib and genetics, as well as such issues in Surgery, with regards to General surgery and Lymph node. His Estrogen receptor study integrates concerns from other disciplines, such as Immunohistochemistry and Estrogen. The study incorporates disciplines such as Carcinoma, DNA ploidy analysis, Categorical variable and Consensus conference in addition to Mammary gland.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon;Gary M. Clark;Steven G. Wong;Wendy J. Levin.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer.
Journal of Clinical Oncology (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
L M McShane;D G Altman;W Sauerbrei;S E Taube.
Breast Cancer Research and Treatment (2006)
PROGNOSTIC AND PREDICTIVE FACTORS IN BREAST CANCER BY IMMUNOHISTOCHEMICAL ANALYSIS
D.C. Allred;Jennet Harvey;M. Berardo;G.M. Clark.
Modern Pathology (1998)
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Jennet M. Harvey;Gary M. Clark;C. Kent Osborne;D. Craig Allred.
Journal of Clinical Oncology (1999)
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Fitzgibbons Pl;Page Dl;Weaver D;Thor Ad.
Archives of Pathology & Laboratory Medicine (2000)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
Lisa M. McShane;Douglas G. Altman;Willi Sauerbrei;Sheila E. Taube.
British Journal of Cancer (2005)
Prognostic Factors in Breast Cancer
Patrick L. Fitzgibbons;Patrick L. Fitzgibbons;David L. Page;Donald Weaver;Ann D. Thor.
Archives of Pathology & Laboratory Medicine (2000)
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
C. Kent Osborne;Valerie Bardou;Torsten A. Hopp;Gary C. Chamness.
Journal of the National Cancer Institute (2003)
Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer
D. C. Allred;G. M. Clark;R. Elledge;S. A. W. Fuqua.
Journal of the National Cancer Institute (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: